Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
NCT07502508
This study is recruiting at 17 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 2 Diabetes
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Biomea Fusion Inc.
- Last updated on ClinicalTrials.gov
- June 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Central Research Associates, LLC dba Flourish Research · Birmingham, AL
California · 4
- Hope Clinical Research · Canoga Park, CA
- Ark Clinical Research · Long Beach, CA
- Catalina Research Institute, LLC · Montclair, CA
- Paradigm Clinical Research Centers, LLC · San Diego, CA
Florida · 3
- Southwest General Healthcare Center · Fort Myers, FL
- Panax Clinical Research · Miami Lakes, FL
- Flourish Research Orlando · Winter Park, FL
Georgia · 1
- David Kavtaradze MD, Inc · Cordele, GA
Nevada · 1
- Excel Clinical Research · Las Vegas, NV
Ohio · 1
- Diabetes and Endocrinology Associates of Stark County · Canton, OH
Texas · 5
- Elligo Health Research, Inc. · Austin, TX
- Zenos Clinical Research · Dallas, TX
- Synergy Group Medical · Houston, TX
- Epic Clinical Research · Lewisville, TX
- Diabetes & Glandular Disease Clinic, P.A. · San Antonio, TX
Virginia · 1
- Burke Internal Medicine and Research · Burke, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.